Clinical trials
Solid Cancers clinical trials
Below are recruiting solid cancers clinical trials, each written for real people, not researchers. We’re tracking 901 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07292038RecruitingPhase 1
Testing NM6603 in advanced solid tumors
This study tests an experimental oral drug called NM6603 in people with advanced solid tumors, especially colorectal cancer or triple-negative breast cancer. It aims to find a safe dose and see how the drug works in the body.
Xiamen, FujianAges 18–75 - NCT07246863RecruitingPhase 2
Testing visugromab and nivolumab with or without docetaxel for advanced lung cancer
This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.
Birmingham, AlabamaAges 18 years+ - NCT07146672RecruitingPhase 1/Phase 2
Super DC cell injection to prevent cancer recurrence after surgery
This trial tests a new immune cell treatment called Super DC cells to see if it can stop tumors from coming back after they have been surgically removed. It is for people with solid tumors who have had complete removal of the cancer and show no signs of remaining disease on scans.
ShanghaiAges 18–80 - NCT07135817Recruiting
Pre-surgery radiation for spinal tumors
This trial tests whether giving focused radiation before surgery can improve treatment for spinal tumors that have spread from other cancers. It may help people who need surgery for a spinal tumor and have a life expectancy of more than 6 months.
GöttingenAges 18 years+ - NCT07098988RecruitingPhase 2
Visugromab plus standard chemo-immunotherapy for lung cancer
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
Birmingham, AlabamaAges 18 years+ - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06936748RecruitingPhase 2
Radiation plus immunotherapy for large relapsed solid tumors
This trial tests a new combination of radiation therapy and two immunotherapy drugs (Iparomlimab and Tuvonralimab) for people whose solid tumors have returned or spread and are too large for standard surgery. The goal is to shrink the tumor and control the cancer.
Nanchang, JiangxiAges 18–75 - NCT06778408RecruitingPhase 2
Hybrid arc palliative radiation therapy for metastasis
This trial tests a new radiation technique for people with cancer that has spread to bones or soft tissues in the chest, belly, or pelvis. The goal is to safely deliver effective palliative radiation to ease symptoms.
Burlington, VermontAges 18 years+ - NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
San Francisco, CaliforniaAges 18 years+ - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT04766515Recruiting
Study of immune checkpoint cancer treatment in real life
This is an observational study that follows adults with solid cancer who are receiving immune checkpoint inhibitor treatments. It aims to learn how these medicines are used and what outcomes may look like in everyday care.
ShanghaiAges 18 years+ - NCT04762862Enrolling by invitation
Testing gene-guided cancer treatment changes in advanced tumors
This trial studies whether measuring changes in your tumor’s genes (from pangenomic quantitative testing) can help guide cancer treatment when standard cures aren’t available. It may help doctors choose therapies based on what your tumor shows.
NiceAges Any age - NCT07613723RecruitingPhase 1
Testing ZI-MA4-1 immunotherapy for advanced solid cancers
This early-stage trial tests a new type of immunotherapy called ZI-MA4-1 in patients with advanced cancers (ovarian, lung, synovial sarcoma, or head and neck) that have stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells that have a specific protein called MAGE-A4.
LondonAges 18–75 - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Chandler, ArizonaAges 18 years+ - NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
Scottsdale, ArizonaAges 18 years+ - NCT07003022RecruitingPhase 2
Two-drug combo for advanced colorectal cancer
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Shanghai, ChinaAges 18–80 - NCT06103669Recruiting
Local treatment for limited cancer spread
This trial tests whether using local treatments (like targeted radiation or ablation) on a few new spots of cancer can help people whose cancer is otherwise stable on their current treatment. It enrolls people with various solid tumors, such as breast, gynecologic, head & neck, sarcoma, or other types.
Sacramento, CaliforniaAges 18 years+ - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT05956587RecruitingPhase 2
Testing two study drugs for advanced lung cancer and other tumors
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Sacramento, CaliforniaAges 18 years+
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid cancers?
- Yes. Clin2 currently lists 901 recruiting solid cancers studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid cancers trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid cancers trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.